In:
Biotechnology and Bioengineering, Wiley, Vol. 119, No. 11 ( 2022-11), p. 3210-3220
Abstract:
Affinity capture is one of the most attractive strategies for simplifying downstream processing. Although it is a key mainstream approach for antibody purification, the same is not true for other biologics such as vaccines, mainly due to the lack of suitable affinity material. In this study, a novel custom affinity system is introduced permitting widespread adoption of affinity capture for the purification of biologics beyond antibodies. This is illustrated here by the development of a one‐step purification process of a mutant form of streptolysin O (SLO), a vaccine candidate against Streptococcus pyogenes infection. The system consists of the association of custom ligands based on the Nanofitin protein scaffold, with Eshmuno® industry‐grade chromatography medium. The Nanofitins were selected for their specificity to the target product. The newly developed affinity medium was used at different column sizes to monitor scalability from process development (1 ml) and robustness verification (5 ml) to pilot (133 ml) and technical (469 ml) runs. The single‐step affinity purification consistently delivered high purity product (above 〉 90%) and improved performances compared with the current three‐step process: reduced process time and footprint (3 to 1 step) and increased product yields (0.31 g vs. 0.04 g of SLO per kg of harvest broth). The custom affinity system herein described can potentially be applied to any biologic for which a specific Nanofitin is identified, thus establishing a platform with a strong impact on the manufacturing of vaccines and other biological targets.
Type of Medium:
Online Resource
ISSN:
0006-3592
,
1097-0290
Language:
English
Publisher:
Wiley
Publication Date:
2022
detail.hit.zdb_id:
1480809-2
detail.hit.zdb_id:
280318-5
SSG:
12
